The move comes after Relitect recently secured a tranched investment of £750,000, which was led by IP Group plc with co-investment from IP Venture Fund II and Scottish Enterprise’s investment arm, Scottish Investment Bank, via the Scottish Co-investment Fund. The investment will support the company to build its internal research and development capability, as well as manufacture and test prototype devices.
Relitect is developing a new electronic device that can detect incredibly low levels of biomarkers in small sample volumes. This approach has the potential to be used across the clinical diagnostics and life sciences industries to support drug development, identify new biomarkers of disease and provide improved disease diagnosis. The team based at BioCity Scotland will lead the research and development required to fully commercialise the technology.
Alan Thomson, Technical Director at Relitect said: “Choosing the right premises was important for the company to ensure that we have the right infrastructure to achieve our short term objectives, as well as our goals for long term growth. We chose BioCity Scotland because of the quality of laboratory space and the minimal work needed to get our laboratory up and running, as well as the comprehensive support available from the Biocity team.”
Dr Diane Harbison, Managing Director of BioCity Scotland said: “We are delighted that Relitect has chosen BioCity Scotland as the place where it will develop its exciting new technology, and we are really looking forward to supporting the ongoing development of the company.”
“As well as providing high spec laboratories and office space, BioCity Scotland also offers access to expertise, finance and a community of like-minded people, and it’s that additional support that really helps our tenant companies to achieve such a high success rate.”